Press Releases

Date Title and Summary  
Toggle Summary Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings
— Poster Presentations Will Discuss Global Screening Data from Aimmune’s Phase 3 PALISADE Trial and Current Approaches to Oral Immunotherapy — BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 19, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for
Toggle Summary Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy
— Phase 2 Clinical Trial Will Explore AR101 Treatment with Adjunctive Dupilumab in Peanut-Allergic Patients — — Trial Design Will Test Potential to Achieve Sustained Unresponsiveness to Peanut Following Treatment — — Conference Call Today at 8:30 a.m. Eastern Time / 5:30 a.m.
Toggle Summary Aimmune Therapeutics to Participate in Three Investor Conferences in September
BRISBANE, Calif. --(BUSINESS WIRE)--Sep. 6, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will be presenting at three upcoming investor
Toggle Summary Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 9, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company overview at the 2017 Wedbush PacGrow Healthcare
Toggle Summary Aimmune Therapeutics Announces Second Quarter 2017 Financial Results
BRISBANE, California --(BUSINESS WIRE)--Aug. 8, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2017 .
Toggle Summary Aimmune Therapeutics’ Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy
— Discovery of T H 2A Cells by Benaroya Research Institute Scientists, Led by Erik Wambre, Ph.D., Could Focus Future Allergy Research — — AR101 Treatment Linked to Decrease in T H 2A Cells in Samples from Peanut-Allergic Patients from ARC001 Trial — BRISBANE, Calif. --(BUSINESS WIRE)--Aug.
Toggle Summary Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
— Trial Will Augment Ongoing Phase 3 PALISADE Trial and Explore Endpoint of Tolerating at Least 1000-mg Dose of Peanut Protein to Support AR101 Regulatory Filings in Europe — BRISBANE, Calif. --(BUSINESS WIRE)--Jul. 5, 2017-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress
BRISBANE, Calif. & HELSINKI--(BUSINESS WIRE)--Jun. 20, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today reported findings from pre-randomization, preliminary clinical data collected from the European
Toggle Summary Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017
— Abstracts Report on Screening Population for PALISADE Phase 3 Clinical Trial and Current Management of Peanut Allergy — BRISBANE, California --(BUSINESS WIRE)--Jun. 15, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food
Toggle Summary Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy
— Final Study Visits Projected Around Year-End 2017; Topline Data Expected in the First Quarter of 2018 — — More Than 97 Percent of Patients Currently On Study Are Through the Up-Dosing Phase — BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 12, 2017-- Aimmune Therapeutics, Inc.